Ascletis' ASC36_35 FDC Shows Superior Weight Loss in Preclinical Data
Event summary
- ASC36_35 FDC demonstrated superior weight loss compared to eloralintide/tirzepatide combination in diet-induced obese (DIO) animal models.
- Preclinical data will be presented in a short oral discussion at the 62nd EASD Annual Meeting on October 1, 2026.
- ASC36_35 FDC is a once-monthly subcutaneous injection co-formulation targeting amylin receptor, GLP-1R, and GIPR.
- Ascletis utilizes its Ultra-Long-Acting Platform (ULAP) technology for the formulation.
The big picture
Ascletis' ASC36_35 FDC represents a strategic push into the obesity treatment market, leveraging its proprietary ULAP technology. The superior preclinical data positions it as a potential first-in-class therapy, competing directly with established combinations like eloralintide/tirzepatide. Success here could solidify Ascletis' role in the metabolic disease space.
What we're watching
- Clinical Translation
- Whether preclinical superiority will translate into human trials and regulatory approval.
- Competitive Positioning
- How ASC36_35 FDC differentiates against existing obesity treatments like eloralintide/tirzepatide combinations.
- Market Adoption
- The pace at which Ascletis can bring this formulation to market given the competitive landscape.
Related topics